Smarter. Stronger. Together: Optimizing Personalized Triple-Negative Breast Cancer Care for Providers and Patients

Download All
Review latest practice-changing data and gain expert insights into the optimization and personalization of care of patients with TNBC, including a Cancer Conversations webinar with discussions about the key areas of consensus and controversy in the management of TNBC, an on-demand webcast, an audio podcast, a downloadable slideset from the live webinar, and focused commentaries.
Laura M. Spring, MD

ClinicalThought

Read this expert commentary discussing a 44-year-old woman with recurring advanced TNBC who received treatment with sacituzumab govitecan, an FDA-approved Trop-2–directed antibody and topoisomerase inhibitor conjugate, in the relapsed/refractory setting.

Laura M. Spring, MD Released: November 14, 2022
Provided by Clinical Care Options, LLC, in partnership with Smart Patients, Inc.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by an educational grant from
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings